Surgery – Means for introducing or removing material from body for... – Infrared – visible light – ultraviolet – x-ray or electrical...
Reexamination Certificate
1999-01-29
2001-12-11
Nguyen, Dave T. (Department: 1633)
Surgery
Means for introducing or removing material from body for...
Infrared, visible light, ultraviolet, x-ray or electrical...
C514S001000, C514S002600
Reexamination Certificate
active
06330472
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to the use of an epithelium-destroying agent to destroy the epithelium of an exocrine gland, particularly the mammary gland, in the prophylactic and therapeutic treatment of disease, in particular cancer.
BACKGROUND OF THE INVENTION
Exocrine glands are glands that release a secretion external to or at the surface of an organ by means of a canal or duct. Examples of exocrine glands include, among others, the mammary glands, prostate, liver, gall bladder, pancreas, kidneys, sweat glands, and salivary glands. Cancers of exocrine glands pose a major health problem, frequently resulting in death. Currently, cancers of the breast and prostate are among the leading causes of death among women and men, respectively.
The mature human breast comprises from six to nine major ducts, which emanate from the nipple, serially branch into ducts and terminate in lobuloalveolar structures (Russo et al., Lab. Invest. 62(3): 244-278 (1990)). This branching network of ducts is composed of epithelial cells in a supporting matrix of connective tissue and endothelial cells.
Tissues removed from the human female breast during surgery and autopsy have been examined in numerous studies directed to the nature and site of origin of neoplastic growth. Subgross sampling and histological confirmation have enabled pathological characterization of entire breasts, leading to the postulation of the existence of four major possible sites of origin of mammary carcinomas, namely ducts, terminal ducts, ductules, and acini (Russo et al., supra). Ductal origin is supported by the presence of more extensive epithelial proliferations, which are presumed to be preneoplastic, in surgically removed cancerous breasts as compared to nonmalignant breasts removed during autopsies (Russo et al., supra).
With a cumulative lifetime risk of a woman developing breast cancer estimated to be 1 in 9, there is an urgent need to develop therapeutic methods of treatment that are more effective, less invasive and accompanied by fewer side effects and prophylactic methods of treatment that are more effective than increased and intensified physical monitoring and far less extreme than radical mastectomy. In spite of the recent discovery of the heritable breast cancer susceptibility loci, BRCA1 (Miki et al., Science 266: 66-71 (1994)) and BRCA2, and other cancer susceptibility loci, and the increasing ability of physicians to identify women with elevated breast cancer risk, prophylactic methods are still currently limited to physical monitoring and prophylactic mastectomy.
In view of the above, it is an object of the present invention to provide a method of locally treating an exocrine gland prophylactically for disease. It is another object of the present invention to provide a method of locally treating an exocrine gland, in particular the mammary gland, prophylactically for cancer. Another object of the present invention is to provide a method of locally treating an exocrine gland therapeutically for disease. Yet another object of the present invention is to provide a method of locally treating a mammary gland therapeutically for cancer. Still yet another object of the present invention is to provide a method of locally treating a mammary gland both therapeutically and prophylactically for cancer. These and other objects and advantages, as well as additional inventive features, will become apparent from the detailed description provided herein.
SUMMARY OF THE INVENTION
The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular the mammary gland, for disease, in particular cancer. The method comprises contacting the ductal epithelium of the exocrine gland, in particular the mammary gland, with an epithelial-destroying agent. The ductal epithelium is preferably contacted with the agent by ductal cannulation. The epithelium-destroying agent is preferably a vector comprising a thymidine kinase gene, which is used in combination with ganciclovir (GCV), which can be systemically administered. Another preferred epithelium-destroying agent is a vector comprising a hypoxanthine phosphoribosyl transferase (HPRT) gene, which is used in combination with hypoxanthine aminopterin thymidine (HAT) nucleotide, which can be systemically administered. Also preferred as an epithelium-destroying agent is a vector comprising a gene, which, upon transformation of a cell of the ductal epithelium and expression therein, induces apoptosis or death of the transformed cell. A preferred apoptosis-inducing gene is bclxs. Other preferred epithelial-destroying agents include a cytolytic virus, such as Vaccinia virus, and ethanol. The preceding methods can additionally comprise contacting the ductal epithelium with a cytokine or hematopoietic growth factor, such as GM-CSF. Also provided by the present invention is a method of treating the ductal epithelium of a mammary gland both therapeutically and prophylactically for cancer. The combined therapeutic/prophylactic method comprises treating the mammary gland therapeutically by surgery, radiation and/or chemotherapy and contacting the ductal epithelium of the mammary gland, either concomitantly or subsequently, with an epithelium-destroying agent, which does not specifically target cancerous cells. The combined therapeutic/prophylactic method can additionally comprise contacting the ductal epithelium with a cytokine or hematopoietic growth factor, such as GM-CSF.
REFERENCES:
patent: 4568673 (1986-02-01), Brooks
patent: 4623660 (1986-11-01), Richardson
patent: 5149527 (1992-09-01), Weisenthal
patent: 5215904 (1993-06-01), Gould et al.
patent: 5236844 (1993-08-01), Basset et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5383849 (1995-01-01), Johlin et al.
patent: 5472441 (1995-12-01), Edwards et al.
patent: 5478556 (1995-12-01), Elliot et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5651964 (1997-07-01), Hung et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5744133 (1998-04-01), Lathe et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5780009 (1998-07-01), Karatzas
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 5837693 (1998-11-01), German et al.
patent: 5858365 (1999-01-01), Faller et al.
patent: 5866550 (1999-02-01), Frisch
patent: 6096874 (2000-08-01), Wallace et al.
patent: 0 118365 (1984-09-01), None
patent: 0 352722 (1990-01-01), None
patent: 0 657174 (1995-06-01), None
patent: WO93/02556 (1993-02-01), None
patent: WO94/09160 (1994-04-01), None
patent: WO94/26915 (1994-11-01), None
Lukac et al. (Cancerlit Database, AN: 94696782, Non-serial, (1993). CCPC-93: Second International Cancer Chemo Prevention Conference, Apr. 28-30, 1993, Germany), 1993.*
Stedman's Medicat Dictionary, p. 438, col. 2, 1995.*
Dorland's Illustrated Medical Dictionary, p. 425, 1994.*
Berkow et al., The Merck Manual of Diagosis and Therapy, 1992, Merck Research Laboratories, Sixteenth Edition, p. 1818.*
Tannock et al., The Basic Science of Oncology, 1992, McGraw-Hill, Inc., Second Edition, pp. 225-227.*
Ariyama et al.Medline, AN: 91185944, International J. Pancreat, 7, 1-3, 37-47, abstract (1990).
Berchem et al.,Cancer Research, 55:735-738 (Feb. 15, 1995).
Bièche et al.,Cancer Research, 54:4274-4276 (Aug. 15, 1994).
Chen et al.,Proc. Natl. Acad. Sci. USA, 91:3054-3057 (Apr. 1994).
Culver et al. “Gene Therapy for Cancer,”TIG, 10(5): 174-178 (1994).
Friedman. “Gene Therapy of Cancer through Restoration of Tumor-Suppressor Functions?”Cancer(supp) 70(6): 1810-1816 (1992).
Frykberg et al., “Overview of the Biology and Management of Ductal Carcinoma in Situ of the Breast,” DatabaseMedline, File Server Stn Karlsruhe, Abstract 94273121 (1994).
Fujiwara et al., “Gene Therapeutics and Gene Therapy for Cancer,”Current Opinion in Oncology, 6:96-105 (1994).
Hanby etal.,Proc. Annu. Meet. Am. Assoc. Cancer Res., 35:A1085 (1994).
Haran et al.,Cancer Research, 54:5511-5514 (Nov. 1, 1994).
Hodgson. “Advances in Vector Systems for Gene Therapy,”Exp Opin Ther. Patents, 5(5)
Johns Hopkins University School of Medicine
Leydig , Voit & Mayer, Ltd.
Nguyen Dave T.
LandOfFree
Prophylactic and therapeutic treatment of the ductal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic and therapeutic treatment of the ductal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic and therapeutic treatment of the ductal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2579283